KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Consolidated Net Income (2016 - 2025)

Boston Scientific's Consolidated Net Income history spans 17 years, with the latest figure at $669.0 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income rose 19.04% year-over-year to $669.0 million; the TTM value through Dec 2025 reached $2.9 billion, up 56.66%, while the annual FY2025 figure was $2.9 billion, 56.66% up from the prior year.
  • Consolidated Net Income for Q4 2025 was $669.0 million at Boston Scientific, down from $756.0 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $795.0 million in Q2 2025 and bottomed at $93.0 million in Q4 2021.
  • The 5-year median for Consolidated Net Income is $380.0 million (2021), against an average of $403.4 million.
  • The largest annual shift saw Consolidated Net Income skyrocketed 3310.0% in 2021 before it tumbled 67.45% in 2022.
  • A 5-year view of Consolidated Net Income shows it stood at $93.0 million in 2021, then surged by 51.61% to $141.0 million in 2022, then skyrocketed by 257.45% to $504.0 million in 2023, then rose by 11.51% to $562.0 million in 2024, then grew by 19.04% to $669.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Consolidated Net Income are $669.0 million (Q4 2025), $756.0 million (Q3 2025), and $795.0 million (Q2 2025).